NHS Migraine Pills Transform Lives as Thousands Benefit from First-Ever Tablets
The National Institute for Health and Care Excellence (NICE) has heralded the rapid take-up of groundbreaking migraine pills, which are transforming the lives of thousands of patients across England. These tablets, the first offered by the NHS to tackle a root cause of migraines, work by stopping the release of a key protein linked to debilitating attacks.
Life-Changing Impact for Patients
Joanne McShane, an NHS health visitor who suffered from migraines for a decade, described the pills as life-changing. After being prescribed atogepant following its approval by NICE, she reported no headaches since starting treatment. "It has restored my life," she said, noting that previous treatments often provided only temporary relief. Her experience reflects a broader trend, with patients experiencing significant improvements in daily functioning and quality of life.
How the Tablets Work
The pills, atogepant and rimegepant, target calcitonin gene-related peptide (CGRP), a protein that causes intense inflammation in the brain's coverings. This mechanism addresses the underlying cause of migraines, unlike previous preventive treatments such as antidepressants, antiepileptics, and beta-blockers, which were not specifically designed for migraines and often came with difficult side effects.
Rapid Uptake and Prescription Trends
NICE reported a rapid increase in prescriptions, with 22,800 people in England prescribed atogepant or rimegepant by their GPs in 2025, more than triple the number in 2024. This figure excludes prescriptions from hospitals and specialist clinics, indicating even broader usage across the NHS. Helen Knight, director of medicines evaluation at NICE, stated, "These tablets are already transforming the lives of thousands of people with migraine in England, and the rapid uptake is very encouraging."
Approval and Accessibility
NICE recommended rimegepant in 2023 for treating and preventing episodic migraines, defined as between four and 14 attacks per month. Atogepant was approved in 2024 for preventing both episodic and chronic migraines, with chronic defined as 15 or more headache days per month. The pills are prescribed to adults when at least three other preventive treatments have failed, but NICE warned of long waiting times for patients who have not exhausted other options, as specialists usually need to initiate treatment.
Challenges and Future Prospects
Dr. Kay Kennis, a GP and neurology specialist in Bradford, highlighted the cost of these medications as a challenge for the NHS, emphasizing the need for appropriate prescribing to avoid wasting resources. However, she noted that these pills offer real improvements in quality of life, enabling patients to continue working, studying, or caring for their families. Experts suggest that better recognition of migraine symptoms in clinical histories could help GPs prescribe treatments earlier, allowing faster access to specialist options like atogepant and rimegepant when needed.
With one in seven Brits suffering from migraines, symptoms including severe pain, nausea, and sensitivity to light and sound, these new tablets represent a significant advancement in migraine care, offering hope to millions of sufferers.
